SPOP mutations occur early in the natural history of prostate cancer (PCa) and are present in about 10% of both clinically localized and metastatic disease, thus representing the most common non-synonymous mutations in PCa [2,5,6]. This evidence concerns the gene SPOP and prostate cancer.